Evonik unveils latest global trial results
- New MetAMINO® ATLAS showcases 19 trials in 12 countries with more than 2 million broilers, layers, swine and aqua species
- Similar animal performance was achieved in all 19 trials when 100 units of methionine hydroxy analog products were replaced with 65 units of MetAMINO®
- Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Essen, Germany. Evonik has released the second edition of its MetAMINO® ATLAS, a comprehensive set of 19 new performance trials investigating the relative bioavailability of supplementary methionine sources in animal diets. The latest studies reconfirm that 65 units of MetAMINO® can replace 100 units of methionine hydroxy analog free acids and its calcium salts (MHA-FA/Ca) in feeds for poultry, swine, and aquatic species without compromising animal performance.
The trials were conducted in experimental settings and under practical conditions at large scale commercial farms in 12 countries with more than two million animals. Some of the largest trials included 838,000 ducks in China, 408,500 broilers in Germany, 217,000 broilers in Brazil, and 120,000 laying hens in China.
“All the results impressively suggest that our 65% bioefficacy concept for MetAMINO® is universally applicable - for all MHA products, in all monogastric farm and aqua species, under any nutritional settings, under any climate and production conditions,” says Dr. Dirk Hoehler, head of the Essential Nutrition business in the Animal Nutrition business line of Evonik. “This means that customers using MetAMINO® can achieve similar animal performance with fewer units of the product, and so reducing feed cost while improving the overall bottom-line.”
The digital version of the MetAMINO® ATLAS 2024 contains four sections: Trials; Videos; Evonik Amino Acid Recommendations for broilers, laying hens, ducks, turkeys, swine and aqua species; and Articles & Abstracts.
“The last section is a comprehensive selection of the latest and most relevant scientific studies that not only cover the nutritional value of DL-methionine compared to other methionine sources, but also describe all the other advantages that come with MetAMINO® such as highest product quality, optimal flowability, precise dosing, convenient storage and easy-to-handle dry product form,” says Nils Niedner, Director Product Management MetAMINO®. “The ATLAS concludes with a meta-analysis and, for the first time, with two papers on the sustainability aspects of MetAMINO®.”
Evonik’s MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein.
A free copy of the digital version of the MetAMINO® ATLAS 2024 is available at metamino.evonik.com
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.